Examine Comprehensive Information on All Major Malignancies, Covering over 1,000 Oncology Drugs Currently in Development
DUBLIN, Ireland--Research and Markets (http://www.researchandmarkets.com/reports/c66120) has announced the addition of "Future Oncology" to their offering.
"Future Oncology" is a comprehensive, analytical review of all aspects of the oncology field for executives, researchers, and market analysts in the pharmaceutical, biotechnology, financial, hospital and other health care related sectors. It provides comprehensive, up-to-date analysis of scientific, technological, clinical and commercial developments in oncology.
To date, "Future Oncology", has presented comprehensive information on all major malignancies, covering over 1,000 oncology drugs in development (by developer/affiliate, mechanism of action, indication and status), as well as numerous other related products, and profiled hundreds of developers worldwide.
For every cancer indication, the publication presents extensive global epidemiology (incidence and mortality), and USA epidemiology by gender, age, disease stage and survival by stage. In addition, descriptions of targets with utility as diagnostic, prognostic or therapeutic applications, in vitro and in vivo diagnostics in development or on the market, and protocols/results from monotherapy and combination trials of approved agents and those in development, are presented as well estimated treatment costs.
"Future Oncology" is published as 12 issues (several double issues) per subscription period, with a free index listing companies/institutions and subjects covered.
Example of some topics covered in this publication include:
- Pancreatic Cancer
- Angiogenesis Inhibitors/Antimetastatic Agents And Targeted Delivery/Gene Transfer Approaches
- Endothelial Monocyte-activating Protein II (IMAP-II)
- Vascular Endothelial Growth Factor (VEGF) Inhibitors
- Urokinase Plasminogen Activator (uPA) System Inhibitors
- Other Antiangiogenesis Agents
- Targeted Drug Delivery
- Targeted Toxins
- Radioimmunoconjugates
- Targeted Cytotoxics
- Gene Transfer
- Oncolytic Viruses
For more information visit http://www.researchandmarkets.com/reports/c66120
Contacts
Research and Markets
Laura Wood, Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com
"Future Oncology" is a comprehensive, analytical review of all aspects of the oncology field for executives, researchers, and market analysts in the pharmaceutical, biotechnology, financial, hospital and other health care related sectors. It provides comprehensive, up-to-date analysis of scientific, technological, clinical and commercial developments in oncology.
To date, "Future Oncology", has presented comprehensive information on all major malignancies, covering over 1,000 oncology drugs in development (by developer/affiliate, mechanism of action, indication and status), as well as numerous other related products, and profiled hundreds of developers worldwide.
For every cancer indication, the publication presents extensive global epidemiology (incidence and mortality), and USA epidemiology by gender, age, disease stage and survival by stage. In addition, descriptions of targets with utility as diagnostic, prognostic or therapeutic applications, in vitro and in vivo diagnostics in development or on the market, and protocols/results from monotherapy and combination trials of approved agents and those in development, are presented as well estimated treatment costs.
"Future Oncology" is published as 12 issues (several double issues) per subscription period, with a free index listing companies/institutions and subjects covered.
Example of some topics covered in this publication include:
- Pancreatic Cancer
- Angiogenesis Inhibitors/Antimetastatic Agents And Targeted Delivery/Gene Transfer Approaches
- Endothelial Monocyte-activating Protein II (IMAP-II)
- Vascular Endothelial Growth Factor (VEGF) Inhibitors
- Urokinase Plasminogen Activator (uPA) System Inhibitors
- Other Antiangiogenesis Agents
- Targeted Drug Delivery
- Targeted Toxins
- Radioimmunoconjugates
- Targeted Cytotoxics
- Gene Transfer
- Oncolytic Viruses
For more information visit http://www.researchandmarkets.com/reports/c66120
Contacts
Research and Markets
Laura Wood, Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.